As an alternative approach, we sought to identify druggable factors that promote EWSR1::FLI1 expression; inhibition of such factors would reduce EWSR1::FLI1 levels and thus function and may reveal therapeutically targetable mechanisms for the treatment of ES. The gene discussed is FLI1; the disease is Ewing sarcoma.